What were the exact results?

On 23 July, BPC-157, KPV and TB-500 were each backed 8 to 6 with one abstention, and MOTS-c 7 to 5 with two abstentions for obesity and osteoporosis. On 24 July, Semax was backed 8 to 5 with one abstention, Epitalon was backed for insomnia, and emideltide was not backed, failing 6 to 7 with one abstention. The abstention counts are as published by Healio, which printed the full board.

Which peptide was rejected, and why does it stand out?

Emideltide, the compound sold in research channels as DSIP, nominated for opioid withdrawal, chronic insomnia and narcolepsy. It stands out because it has the deepest human record of the seven, with clinical literature going back to 1981, while MOTS-c, which the committee backed, had no human clinical studies at all according to FDA's own review. Emideltide's problem was that its evidence is contradictory rather than absent.

Does the rejection make DSIP illegal?

No, and it was not legal-by-default before. The vote concerns whether United States compounding pharmacies may prepare it on a prescription. It changes nothing about EU classification, and FDA is not bound by the committee in either direction.

Why do the vote totals differ between substances?

The totals range from 12 to 15 votes cast. Temporary voting members were seated for this meeting, and the former FDA official Peter Lurie, quoted by Bloomberg Law, described those new members as mostly confined to certain peptides, which accounts for part of the variation. We can see the effect in the published tallies but cannot document the mechanism precisely, so we do not offer readers an explanation we cannot source.

What has the FDA done since the vote?

Nothing that has been published. As of 25 July 2026 we queried the Federal Register directly and found no post-meeting document, no proposed rule and no docket action arising from the votes. The related entries are the pre-meeting notice of 16 April, a routine renewal of the committee's charter on 30 April and two unrelated 503B items.

How long before anything actually changes in the US?

Nobody has committed to a timeline. The law firm Orrick describes the chain as FDA deciding whether to accept the recommendation, publishing a Notice of Proposed Rulemaking, taking public comments for typically 60 to 90 days, then issuing a final rule, and puts the full cycle at typically 12 to 24 months. ABC News wrote that it can take up to a year. Both are outside estimates; FDA has published none.

Did the committee follow the FDA's own scientists?

Not on six of the seven. FDA's briefing documents proposed not adding any of the seven substances to the list, and the committee voted the other way on six of them. On the seventh, emideltide, the committee agreed with FDA and voted it down. That conflict, rather than the tallies themselves, is what made the meeting newsworthy.

Does any of this change the legal position in the EU?

No. Section 503A is United States law about American compounding pharmacies. None of these substances is authorised as a medicine in the EU, we found no EMA or national statement referencing the vote, and the only EU peptide document in this period is an EMA scientific guideline on manufacturing synthetic peptides that took effect on 1 June 2026 and does not mention compounding.

What does this mean for research use of these compounds?

Nothing legally. They remain unapproved research compounds in the EU and we supply them for laboratory use only, not for human consumption. What has changed is informational: seven substances now carry a public, agency-written evidence assessment, and five more will get one before February 2027.

Where can the underlying documents be read?

FDA published a briefing document for each substance ahead of the meeting. Our summary of what those documents say about MOTS-c, Semax, Epitalon and emideltide is linked in this article, along with our write-up of what the day-one vote legally is. The primary documents themselves are on fda.gov under the meeting materials for the 23 and 24 July 2026 meeting.

Six of Seven: The Complete FDA Peptide Vote, the One That Failed, and the Five That Come Next

Q: Did the FDA approve these peptides?

No. An FDA advisory committee recommended adding six of seven substances to the Section 503A bulk drug substances list, which governs what United States compounding pharmacies may prepare on a prescription. No clinical trial was run or passed, no drug became an approved medicine, and the votes are non-binding on the agency.

Q: Why do sources give different numbers for epitalon?

Because they do. STAT News reports 7 votes to 4 without recording an abstention, Healio reports the same result as 7 yes, 4 no and 1 abstain, and RAPS Regulatory Focus reports 7 to 5 with one abstention. Two of the three outlets we could read support the first reading, which is what we print, but the discrepancy is unresolved and we say so rather than picking a number quietly.

Q: How many votes were actually cast?

More than seven. The committee voted separately on the free base and on the acetate form of every substance, and on Healio's full board the tally came out the same for both forms in each case. Seven substances were considered; the number of individual votes was roughly double that.

Q: Which peptides are up next?

A second Pharmacy Compounding Advisory Committee meeting is expected before the end of February 2027, covering LL-37, GHK-Cu, melanotan II, dihexa acetate and PEG-MGF, according to analysis by the law firm Orrick published on 21 July 2026.

Important notice: This article reports a United States regulatory proceeding for scientific information only. None of the substances discussed is an approved medicine in the EU or the United States, and we supply them as research compounds, not for human consumption. Nothing here is a dosing recommendation, a protocol or legal advice. We sell several of the compounds named below, which gives us an obvious interest in how this reads.

TL;DR: the full board, now that both days have reported

What happened: Over 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the Section 503A bulk drug substances list. It backed six and declined one. Day one: BPC-157, KPV and TB-500 each cleared 8 to 6 with one abstention. MOTS-c cleared more narrowly, 7 to 5 with two abstentions. Day two: Semax cleared 8 to 5 with one abstention. Epitalon was backed for insomnia. Emideltide, the compound sold in research channels as DSIP, failed 6 to 7 with one abstention, the only one of the seven the committee declined to back. Still not an approval: every vote was advisory and non-binding. FDA's own scientific reviewers proposed adding none of the seven; the committee overrode them on six and agreed with them on the seventh, emideltide. Nothing has happened since: as of 25 July there is no FDA statement, no docket action and no Federal Register document arising from the votes. We checked the Federal Register directly. What comes next matters more: a second meeting is expected before the end of February 2027, covering LL-37, GHK-Cu, melanotan II, dihexa acetate and PEG-MGF.

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

KPVregeneration

Anti-inflammatory tripeptide derived from alpha-MSH (positions 11-13). Inhibits NF-kB signaling, supports gut barrier integrity, and shows antimicrobial activity. A targeted approach to inflammation research without broad immunosuppression.

TB-500regeneration

Full-length 43-amino-acid Thymosin Beta-4, a naturally occurring repair protein, independently confirmed by a third-party CoA from Janoshik. Promotes cell migration and new blood vessel formation for systemic tissue healing. Especially researched for muscle, tendon, and cardiac repair.

MOTS-clongevity

Mitochondrial-derived signaling peptide (16 amino acids) that mimics the effects of exercise at the cellular level. Activates AMPK, improves glucose uptake, and enhances fat metabolism - a key tool in metabolic and longevity research.

The complete tally

Both days have now been reported by named outlets, so the full board can be printed. Every one of these votes was a recommendation to add the substance to the list that United States compounding pharmacies may prepare on a prescription. None of them is a drug approval.

Substance	Day	Use the panel considered	Outcome
BPC-157	23 July	Ulcerative colitis	Backed, 8 to 6, one abstention
KPV	23 July	Wound healing and inflammatory conditions	Backed, 8 to 6, one abstention
TB-500	23 July	Wound healing	Backed, 8 to 6, one abstention
MOTS-c	23 July	Obesity and osteoporosis	Backed, 7 to 5, two abstentions
Semax	24 July	Migraine, cerebral ischemia, trigeminal neuralgia	Backed, 8 to 5, one abstention
Epitalon	24 July	Insomnia	Backed, 7 to 4, one abstention
Emideltide (DSIP)	24 July	Opioid withdrawal, chronic insomnia, narcolepsy	Not backed, 6 to 7, one abstention

BPC-157

Day: 23 July
Use the panel considered: Ulcerative colitis
Outcome: Backed, 8 to 6, one abstention

KPV

Day: 23 July
Use the panel considered: Wound healing and inflammatory conditions
Outcome: Backed, 8 to 6, one abstention

TB-500

Day: 23 July
Use the panel considered: Wound healing
Outcome: Backed, 8 to 6, one abstention

MOTS-c

Day: 23 July
Use the panel considered: Obesity and osteoporosis
Outcome: Backed, 7 to 5, two abstentions

Semax

Day: 24 July
Use the panel considered: Migraine, cerebral ischemia, trigeminal neuralgia
Outcome: Backed, 8 to 5, one abstention

Epitalon

Day: 24 July
Use the panel considered: Insomnia
Outcome: Backed, 7 to 4, one abstention

Emideltide (DSIP)

Day: 24 July
Use the panel considered: Opioid withdrawal, chronic insomnia, narcolepsy
Outcome: Not backed, 6 to 7, one abstention

Three things about that table worth knowing

The epitalon number is not settled. STAT News reports 7 votes to 4 and does not record an abstention. Healio prints the same result with one: 7 yes, 4 no, 1 abstain. RAPS Regulatory Focus reports 7 to 5 with one abstention. Two of the three outlets we could read ourselves support the first reading, so that is what the table carries, but the discrepancy is real and we are not going to hide it. The abstention counts across the whole board are as published by Healio; STAT and RAPS report several of the same votes without them. There were more votes than there were substances. The committee voted separately on the free base and on the acetate form of every substance, and on Healio's full board the tally came out the same for both forms in each case. So the correct sentence is that seven substances were considered, not that seven votes were cast. The totals do not add up to a constant panel size, ranging from 12 to 15 votes cast depending on the substance. Temporary voting members were seated for this meeting, and the former FDA official Peter Lurie, quoted by Bloomberg Law, described the new members as "mostly confined to certain peptides". We can see the effect in the numbers; we cannot responsibly explain it in detail, so we do not.

The one that failed, and why it is the interesting one

Emideltide is the international non-proprietary name for delta sleep-inducing peptide, the compound sold in research channels as DSIP. It was nominated for opioid withdrawal, chronic insomnia and narcolepsy, and it is the only substance of the seven the committee declined to back.

Here is what makes that worth a paragraph rather than a footnote. Of the seven, emideltide has by far the deepest human record. Its clinical literature runs back to 1981, and FDA's own briefing document reviewed six trials in chronic insomnia, plus a narcolepsy case and two opioid-withdrawal studies. Compare that with MOTS-c, which the committee backed on day one and for which FDA's reviewers reported finding no human clinical studies at all.

So the compound with the most human data was rejected, and a compound with none was recommended. The explanation is not that the panel weighed the evidence and found emideltide wanting on volume. It is that emideltide's evidence is contradictory: some of those insomnia trials reported an effect, a double-blind placebo-controlled trial in 16 subjects found none, and the authors of another concluded the effects were of little clinical significance. Having evidence that points in two directions is a weaker position in front of a committee than having no evidence and a plausible story.

What a rejection here does and does not mean

It does not make emideltide illegal, and it was not legal-by-default before. It means the committee did not recommend adding it to the list of substances United States pharmacies may compound on a prescription. FDA remains free to disagree with the committee in either direction: it is not bound by a yes and it is not bound by a no. For the EU nothing changes at all, in either case.

DSIPcognitive

DSIP (Delta Sleep-Inducing Peptide), a nonapeptide isolated in 1977. Research material for sleep, HPA-axis, and stress regulation. Research-grade lyophilized powder, laboratory use only.

Semaxcognitive

Brain-boosting nootropic peptide derived from ACTH. Increases BDNF (brain-derived neurotrophic factor), enhances focus, memory, and mental clarity. Widely used in Russian clinical practice for cognitive enhancement.

Epitalonlongevity

Tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase, the enzyme responsible for maintaining telomere length. One of the most studied peptides in longevity research, developed by Prof. Khavinson at the St. Petersburg Institute of Bioregulation.

What actually happens next

This is where most coverage stops, and it is the part that determines whether any of this matters in practice.

The votes are advisory. As FDA's position was summarised by the law firm Hyman, Phelps and McNamara on the day of the second vote, the agency "will continue reviewing the comments and data submitted through the docket and will announce any final decision through notice-and-comment rulemaking, not at the PCAC Meeting". Nothing was decided in that room.

The procedural chain, as set out by the law firm Orrick in an analysis published two days before the meeting opened, runs like this: FDA must first decide whether to accept the recommendation, then publish a Notice of Proposed Rulemaking, then take public comments, typically 60 to 90 days, then issue a final rule. Orrick puts the full cycle at typically 12 to 24 months. ABC News, in its own editorial voice, wrote that the process "can take up to a year". Those are two estimates from two interested professional observers, not an FDA commitment, and FDA has published no timeline of its own.

We checked whether anything has moved

As of 25 July 2026 the answer is no. We queried the Federal Register directly for every 2026 document mentioning bulk drug substances and for every Pharmacy Compounding Advisory Committee document since June. What comes back is the pre-meeting notice of 16 April, a routine notice renewing the committee's charter on 30 April, an unrelated 503B clinical-need list from 1 May and its comment-period extension from 26 June. There is no post-meeting FDA statement, no proposed rule and no docket action. Anyone telling you the rules changed this week is describing something that has not happened.

The five that come next, and why this one matters more to us

The same Orrick analysis notes that a second Pharmacy Compounding Advisory Committee meeting is expected before the end of February 2027, covering five further peptides: LL-37, GHK-Cu, melanotan II, dihexa acetate and PEG-MGF.

Three of those five are compounds we list. That is the reason this article exists rather than a second write-up of a vote we already covered: the substances in the next round are closer to the centre of a European research catalogue than the substances in this one, and the same pattern will repeat. FDA's scientists will publish briefing documents assessing each substance, those documents will be the most rigorous public evidence summaries that exist for several of them, and the committee may again vote against its own agency's reviewers.

What we will do with that

When those briefing documents publish, we will read them and write up what they say, including the parts that are unflattering to compounds we sell. That is what we did with the July documents: FDA found no human clinical studies for MOTS-c, only two usable and negative human references for Semax, and a mechanistic cancer question for Epitalon, and we published all three. Our write-up of those assessments is here, and the day-one vote and what it legally is sits here.

The framing problem, stated plainly

Within hours of the first vote, "the FDA approved peptides" was circulating. It is worth being precise about why that is wrong, because the error survives every correction.

An approval means a sponsor ran clinical trials, submitted them, and the agency judged the drug safe and effective for a stated use. None of that happened here. What happened is that an advisory committee recommended adding substances to a list of ingredients that pharmacies may compound on a prescription, which is a question about pharmacy practice rather than about whether a compound works. Pharmaceutical Executive put it as directly as anyone: "The votes do not make the peptides FDA-approved drugs, instead they represent a recommendation that the compounds will be added to a list of substances that compounding pharmacies are permitted to prepare for patients with a prescription."

The word also appears loosely in professional coverage. The law-firm blog that gave us the most detailed vote breakdown is headlined with the word "approves". The body of the same post says the votes are advisory. If specialists slip, general readers will too.

Not everyone in the room was pleased

The panel that produced these recommendations was expanded in June 2026. ABC News reports that eight members were recently appointed under Health Secretary Robert F. Kennedy Jr. and that six of those eight run clinics offering peptides. NBC News quotes Peter Lurie, a former FDA official, saying "The Wild West is about to become wilder". We could not read the NBC article body directly, so we attribute that quote through NBC rather than presenting it as something we verified at source. Whichever way a reader leans on all this, the underlying fact is not in dispute: FDA's own scientific reviewers proposed adding none of the seven substances, and the committee voted against them on six of the seven. On emideltide the committee agreed with FDA and voted it down.

Where this leaves a researcher in Europe

Nowhere new. Section 503A is a provision of the United States Federal Food, Drug and Cosmetic Act governing what American compounding pharmacies may prepare. It has no legal effect on how any of these compounds is classified in the European Union, none of them is authorised as a medicine here, and we could find no EMA, BfArM or other EU-level statement referencing the vote at all. The only EU peptide document in this period is an EMA scientific guideline on the development and manufacture of synthetic peptides, which took legal effect on 1 June 2026 and does not mention compounding or the American list.

What changes for a European reader is informational, not legal: seven substances now have a public, adversarial, agency-written evidence assessment attached to them, and five more will get one before February 2027. That is genuinely useful, and it is the part of this story with a shelf life longer than a news cycle.

Longevity & Anti-Aginglongevity

Mitochondrial function, NAD+ metabolism, telomere maintenance

Backed by the committee in July

On the docket for the next meeting

LL-37regeneration

Cathelicidin-derived antimicrobial peptide (37 amino acids). Researched for innate immunity, antimicrobial activity, and wound-healing pathways. ≥98% HPLC purity with Janoshik CoA.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

Melanotan-2growth

Tanning peptide that activates melanin production in the skin. Stimulates melanocyte receptors for natural UV-free pigmentation. Also researched for appetite regulation and libido effects.

FAQ

Sources

Lawrence L, Todd S. "FDA advisory panel narrowly rejects compounding of one peptide, backs two others." STAT News, 24 July 2026. https://www.statnews.com/2026/07/24/fda-peptide-compounding-panel-backs-epitalon-rejects-emideltide/
Eglovitch JS. Regulatory Focus (RAPS). Day one, "FDA advisory committee backs two controversial peptides," 23 July 2026: https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html . Day two, "FDA advisory committee backs two more peptides, rejects one for compounding list," 24 July 2026, source of the 7 to 5 epitalon reading: https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html
Palmer KL, Snow CD, Bass M. FDA Law Blog (Hyman, Phelps and McNamara), 24 July 2026, including the per-form vote breakdown and FDA's stated position on rulemaking. https://www.thefdalawblog.com/2026/07/peptide-l-wave-pcac-approves-four-bulk-drug-substances-for-the-503a-list/
Phengsitthy N. "FDA advisers back looser rules for six peptides, reject one." Bloomberg Law, 24 July 2026. https://news.bloomberglaw.com/health-law-and-business/fda-review-committee-rejects-first-peptide-in-second-day-hearing
Daniel Y. "FDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?" ABC News, 24 July 2026. https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
Jacobus N. Pharmaceutical Executive, 24 July 2026, on what the votes do and do not do. https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides
Ravitz GC, Esfahani S, Johnson T, Sherer JD, Joseph AM. "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting." Orrick, 21 July 2026, source of the rulemaking chain, the 12 to 24 month estimate and the five substances expected at the next meeting. https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting
Federal Register API, queried 25 July 2026 for all 2026 documents mentioning bulk drug substances and all Pharmacy Compounding Advisory Committee documents since 1 June 2026. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
European Medicines Agency. "Development and manufacture of synthetic peptides," scientific guideline EMA/CHMP/CVMP/QWP/367182/2025, legal effect 1 June 2026. https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline
"FDA committee recommends looser restrictions for several peptides." Healio, 24 July 2026, source of the full seven-row vote board including the abstention counts and the per-form votes. https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides
"FDA Adds More Peptide Panel Experts After Conflict Criticism." Bloomberg Law, source of the eight temporary voting members and the Peter Lurie characterisation of their remit. https://news.bloomberglaw.com/health-law-and-business/fda-adds-more-peptide-panel-experts-after-conflict-criticism

Research disclaimer: All content serves scientific information only. The substances discussed are not approved medicines in the EU or the United States and are supplied by us for laboratory research use only, not for human consumption. Vote tallies are reported as published by the named outlets and, where those outlets disagree, both readings are given.